• Type: Antidepressant
  • Dosage Forms: tablet, sustained-release tablet, extended-release tablet
  • Dosage Strengths: tablet: 75, 100mg; sustained-release tablet (Wellbutrin SR): 100, 150, 200mg; extended-release tablet (Wellbutrin XL): 150, 300mg; extended-release tablet (Aplenzin): 174, 348, 522mg; extended-release tablet (Forfivo XL): 450mg; extended-release tablet (Zyban): 150mg
  • Routes of Administration: PO
  • Common Trade Names: Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban, Forfivo XL, Budeprion SR, Aplenzin, Buproban

Adult Dosing

  • Immediate release: 100-150mg PO 2-4 times daily
  • Sustained release: 150mg PO 1-2 times daily

Pediatric Dosing

Safety/efficacy not established

Special Populations

  • Pregnancy Rating: C
  • Lactation risk: infant risk cannot be ruled out
  • Renal dosing: dose reduction or avoidance recommended
  • Hepatic dosing: dose reduction or avoidance recommended


  • Allergy to class/drug
  • Use of MAOI, linezolid, or methylene blue concomitantly or within past 2 weeks
  • Seizure disorder
  • Condition which lowers seizure threshold (e.g. abrupt cessation of ETOH, benzos, or AEDs, anorexia/bulimia, electrolyte derangement)

Adverse Reactions


  • Seizure
  • Cardiac dysrhythmia
  • Angle-closure glaucoma
  • Suicidal ideation, worsening depression, mania, psychosis


  • Insomnia
  • Dizziness, tremor
  • Headache
  • Nausea, constipation
  • Tachyarrhythmia (10.8% )
  • Pruritus, rash, urticaria
  • Arthralgia, myalgia
  • Tinnitus
  • Xerostomia, pharyngitis


  • Half-life: 14-33h
  • Metabolism: Hepatic, CYP2B6
  • Excretion: Mostly renal

Mechanism of Action

  • Exact therapeutic mechanism unknown. Weakly inhibits neuronal uptake of dopamine and norepinephrine
  • Structurally belongs to the class of synthetic cathinones
    • Due to structure, can cause false positive screen for amphetamine on UDS[1]


See Also


  1. Casey ER, Scott MG, Tang S, Mullins ME. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay. J Med Toxicol. 2011;7(2):105-108. doi:10.1007/s13181-010-0131-5